Long-Term Outcomes of Rheohaemapheresis in the Treatment of Dry Form of Age-Related Macular Degeneration

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F13%3A10192011" target="_blank" >RIV/00179906:_____/13:10192011 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00843989:_____/13:E0103702 RIV/00216208:11150/13:10192011

Výsledek na webu

<a href="http://www.hindawi.com/journals/joph/2013/135798/" target="_blank" >http://www.hindawi.com/journals/joph/2013/135798/</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1155/2013/135798" target="_blank" >10.1155/2013/135798</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Long-Term Outcomes of Rheohaemapheresis in the Treatment of Dry Form of Age-Related Macular Degeneration

Popis výsledku v původním jazyce

Purpose. Determining long-term effects of rheohaemapheresis on the dry form of age-related macular degeneration. Methods. This study evaluates 19 patients, average age of 67.6 years, treated with rheohaemapheresis and 18 patients, average age of 72.8 years, comprising the control group. Minimum follow up period was 3.5 years. Each treated patient received a series of 8 sessions of rheohaemapheresis of 1.5 plasma volumes within 10 weeks. We measured the drusenoid pigment epithelium detachment (DPED), best-corrected visual acuity (BCVA), electroretinography (ERG), and rheological parameters. Results. In the treatment group, the baseline BCVA was 0.74 (0.36-1.0) 95% CI and BCVA after 3.5 years was 0.79 (0.41-1.0) 95% CI ( ). In the control group, the baseline BCVA was 0.71 (0.15-1.0) 95% CI and BCVA after 3.5 years decreased to 0.7 (0.32-0.87) 95% CI ( ). Baseline DPED was 6.78 +- 3.79 mm2; after 3.5 years, it decreased to 4.13 +- 3.84 mm2 ( ). In the control group, the baseline DPED was

Název v anglickém jazyce

Long-Term Outcomes of Rheohaemapheresis in the Treatment of Dry Form of Age-Related Macular Degeneration

Popis výsledku anglicky

Purpose. Determining long-term effects of rheohaemapheresis on the dry form of age-related macular degeneration. Methods. This study evaluates 19 patients, average age of 67.6 years, treated with rheohaemapheresis and 18 patients, average age of 72.8 years, comprising the control group. Minimum follow up period was 3.5 years. Each treated patient received a series of 8 sessions of rheohaemapheresis of 1.5 plasma volumes within 10 weeks. We measured the drusenoid pigment epithelium detachment (DPED), best-corrected visual acuity (BCVA), electroretinography (ERG), and rheological parameters. Results. In the treatment group, the baseline BCVA was 0.74 (0.36-1.0) 95% CI and BCVA after 3.5 years was 0.79 (0.41-1.0) 95% CI ( ). In the control group, the baseline BCVA was 0.71 (0.15-1.0) 95% CI and BCVA after 3.5 years decreased to 0.7 (0.32-0.87) 95% CI ( ). Baseline DPED was 6.78 +- 3.79 mm2; after 3.5 years, it decreased to 4.13 +- 3.84 mm2 ( ). In the control group, the baseline DPED was

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FF - ORL, oftalmologie, stomatologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT14037" target="_blank" >NT14037: Optimalizace léčby suché formy věkem podmíněné makulární degenerace rheohemaferézou</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Ophthalmology

ISSN

2090-004X

e-ISSN

—

Svazek periodika

Neuveden

Číslo periodika v rámci svazku

December

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

8

Strana od-do

—

Kód UT WoS článku

000328970300001

EID výsledku v databázi Scopus

—